NervGen Pharma Corp. (NGEN) shareholders
Close on Nov 17, 2026Market cap $156.11MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NGEN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 4,000,000 | 5.02% | $8.24M | New | 9.53% |
| Rock Springs Capital Management LP | 1,208,231 | 1.52% | $2.49M | New | 0.12% |
| DAFNA Capital Management LLC | 1,050,000 | 1.32% | $2.16M | New | 0.41% |
| Ghisallo Capital Management LLC | 1,000,000 | 1.26% | $2.06M | New | 0.04% |
| Armistice Capital, LLC | 678,000 | 0.85% | $1.40M | New | 0.02% |
| LMR Partners LLP | 600,000 | 0.75% | $1.24M | New | 0.00% |
| Marshall Wace, Llp | 435,962 | 0.55% | $898.08K | +235,603 | 0.00% |
| UBS Group AG | 379,726 | 0.48% | $782.24K | +318,209 | 0.00% |
| Stonepine Capital Management, LLC | 271,678 | 0.34% | $559.66K | New | 0.32% |
| Jane Street Group, LLC | 270,750 | 0.34% | $557.75K | New | 0.00% |
| Woodline Partners LP | 250,500 | 0.31% | $516.03K | New | 0.00% |
| PFG Investments, LLC | 217,500 | 0.27% | $448.05K | +16,500 | 0.02% |
| Bank Of America Corp /De/ | 186,200 | 0.23% | $383.57K | −14,456 | 0.00% |
| Royal Bank of Canada | 176,075 | 0.22% | $363.00K | +4,114 | 0.00% |
| Quadrature Capital Ltd | 134,518 | 0.17% | $277.11K | New | 0.00% |
| Bank Of Montreal /Can/ | 78,394 | 0.10% | $284.38K | +15,494 | 0.00% |
| Integrated Wealth Concepts LLC | 74,215 | 0.09% | $152.88K | −12,600 | 0.00% |
| Captrust Financial Advisors | 64,423 | 0.08% | $132.71K | +2,056 | 0.00% |
| Geode Capital Management, LLC | 58,040 | 0.07% | $119.56K | New | 0.00% |
| Osaic Holdings, Inc. | 51,093 | 0.06% | $105.25K | +11,102 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 62 | 12M | 15.1% | 20 / 20 | 7 / 3 | 10M | 0M |
| Q1 2026 | 45 | 2M | 2.1% | 44 / 0 | 0 / 0 | 2M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2022 | 2 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1 funds held NGEN in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NGEN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 15,362 | 0.02% | $31.80K | 0.00% | May 31, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 10 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NervGen Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,910 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?